4//SEC Filing
TAYTON-MARTIN HELEN KATRINA 4
Accession 0001104659-18-002678
CIK 0001621227other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:21 PM ET
Size
8.6 KB
Accession
0001104659-18-002678
Insider Transaction Report
Form 4
TAYTON-MARTIN HELEN KATRINA
Chief Operating Officer
Transactions
- Award
Option to purchase Ordinary Shares
2018-01-12+687,984→ 687,984 totalExercise: $1.30Exp: 2028-01-12→ Ordinary Shares (687,984 underlying) - Award
Option to purchase Ordinary Shares
2018-01-12+153,648→ 153,648 totalExercise: $0.00Exp: 2028-01-12→ Ordinary Shares (153,648 underlying)
Footnotes (4)
- [F1]The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 171,996 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 14,333 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 38,412 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 38,412 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001661780
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:21 PM ET
- Size
- 8.6 KB